App-Quantinova.ai

An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease

B Verstockt - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

Ustekinumab

Magnification endoscopy with optical chromoendoscopy for in vivo assessment of histological inflammation in patients with inflammatory bowel disease

E Klenske - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease

N/A

Nationwide incidence and prevalence of paediatric inflammatory bowel disease in Scotland 2015–2017 demonstrates the highest paediatric prevalence rate recorded worldwide

C Burgess - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Inflammatory bowel disease unclassified

N/A

Rising depression and antidepressant use amongst inflammatory bowel disease patients

J Blackwell - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Inflammatory bowel disease

N/A

Multi-parameter datasets are required to identify the true prevalence of IBD: The Lothian IBD Registry (LIBDR)

G-R Jones - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Mucosal tissue short chain fatty acids contribute to prediction of pouchitis in restorative proctocolectomy

J Segal - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pouchitis

N/A

Circulating classical monocytes and intestinal macrophages exhibit reduced response to IL-10 in IBD

I Hoti - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Interleukin-10

The anti-inflammatory effects of niclosamide on cytokines produced by PBMCs derived from IBD patients

U N Shivaji - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

DMSO

Machine learning approaches to identify prognosis indicators from microbiome data

M Madgwick - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Constitutive activity of the cation channel TRPM8 regulates monocyte to macrophage transition in humans to control intestinal inflammation

E Hornsby - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

AG-3-5

A resting state fMRI study in patients with active Crohn’s disease

G Thapaliya - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Crohn's disease

N/A

Plasma acetic acid, propanoic acid, and isobutyric acid are associated with treatment response in pouchitis patients treated with antibiotics

J Segal - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pouchitis

N/A

Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn’s disease

A Lewis - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

A novel porcine model of Crohn’s disease anastomotic stricture

M Lukas - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Crohn's disease

N/A

Exploring mucosal function as a clinical endpoint in ulcerative colitis

S Kjaergaard - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

Occlusal-HP Topical

SMAD7 shows a biphasic expression pattern during progression of ulcerative colitis-associated colorectal cancer

P Chandrasinghe - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Colitic cancer

N/A

The transcriptomic signature of IL-23-treated lamina propria mononuclear cells is significantly enriched for genes in the Th17 pathway and is enriched in active UC

J Digby-Bell - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

N/A

Urinary formate and glycine are associated with treatment response in patients treated with antibiotics for pouchitis

J Segal - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Pouchitis

N/A

CD4 T-cell transcriptome analysis at baseline predicts clinical remission to anti-TNF agents in ulcerative colitis (UC)

S Subramanian - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Signalling and transcriptional network propagation uncovers novel ulcerative colitis pathogenetic pathways from single-nucleotide polymorphisms

D Modos - European Crohn’s and Colitis Organisation (ECCO) , 2019

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Ulcerative colitis

N/A

Filters

45280 Abstracts